Keywords
Prognosis
Immunoparesis
Classical Immunoparesis
Overall Survival
How to Cite
Abstract
Multiple myeloma (MM) is a very heterogeneous hematological malignancy characterized by the proliferation of clonal plasma cells in bone marrow, leading to a decrease in normal plasma cells. The immune system plays a key role in both the pathogenesis and the prognosis of MM. A wide range of immune dysfunctions can be demonstrated in most patients at diagnosis. The presence of suppression of uninvolved immunoglobulins, also called classical immunoparesis (CIP), can be demonstrated in the majority of newly diagnosed MM (NDMM) patients, although its prognostic impact remains controversial in previous studies. Our population-based study confirms that CIP is present in most NDMM patients. It is associated with several well-known prognostic factors, including the International Staging System, being more frequent in late stages. Median overall survival in CIP+ patients was 62.4 months (CI 95%, 52.1-72.7), whereas it was not reached for those CIP- (p=0.150). Despite the absence of statistical significance, the multivariate Cox proportional hazards model endorses CIP as an independent and strong prognostic factor for overall survival in NDMM, besides age, performance status, total serum cholesterol, and the presence of 1q gain. More comprehensive studies, including complete immune profiling, are warranted to establish the role of CIP in the context of the current and emerging prognostic factors in NDMM.
References
Schavgoulidze A, Cazaubiel T, Perrot A, Avet-Loiseau H, Corre J. Multiple Myeloma: Heterogeneous in Every Way. Cancers. 2021; 13(6):1285. https://doi.org/10.3390/cancers13061285
Ríos-Tamayo R, Sainz J, Jurado M, Puerta JM, González PA, Romero A, et al. Multiple myeloma with prior precursor disease shows better outcome. Blood. 2015;126(21):1756. https://doi.org/10.1182/blood.V126.23.1756.1756
Rajkumar SV, Dimopoulos MA, Palumbo A, Bladé J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol.2014 Nov; 15(12):e538-48. https://doi.org/10.1016/s1470-2045(14)70442-5
Krejcik J, Barnkob MB, Nyvold CG, Larsen TS, Barington T, Abildgaard N. Harnessing the Immune System to Fight Multiple Myeloma. Cancers. 2021 Sep 10; 13(18):4546. https://doi.org/10.3390/cancers13184546
Ríos-Tamayo R, Puig N, Algarín M, García de Veas Silva JL, Barbosa N, Encinas C, et al. The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach. Diagnostics 2021; 11(11):2020. https://doi.org/10.3390/diagnostics11112020
Pérez-Persona E, Vidriales MB, Mateo G, García-Sanz R, Mateos MV, de Coca AG, et al. New Criteria to Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance and Smoldering Multiple Myeloma Based on Multiparameter Flow Cytometry Analysis of Bone Marrow Plasma Cells. Blood. 2007;110(7):2586-2592. https://doi.org/10.1182/blood-2007-05-088443
Hájek R, Sandecka V, Špička I, Raab M, Goldschmidt H, Beck S, et al. Identification of Patients with Smouldering Multiple Myeloma at Ultra-High Risk of Progression Using Serum Parameters: The Czech Myeloma Group Model. Br J Haematol. 2020; 190(2):189-197. https://doi.org/10.1111/bjh.16572
Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, et al. Preserved Levels of Uninvolved Immunoglobulins Are Independently Associated with Favorable Outcome in Patients with Symptomatic Multiple Myeloma. Leukemia. 2014;28(10):2075-9. https://doi.org/10.1038/leu.2014.110
Sørrig R, Klausen TW, Salomo M, Vangsted AJ, Frølund UC, Anderse KT, et al. Immunoparesis in Newly Diagnosed Multiple Myeloma Patients: Effects on Overall Survival and Progression Free Survival in the Danish Population. PLoS One. 2017 Dec; 12(12):e0188988. https://doi.org/10.1371/journal.pone.0188988
Heaney JLJ, Campbell JP, Iqbal G, Cairns D, Richter A, Child JA, et al. Characterisation of Immunoparesis in Newly Diagnosed Myeloma and Its Impact on Progression-Free and Overall Survival in Both Old and Recent Myeloma Trials. Leukemia. 2018; 32(8):1727-1738. https://doi.org/10.1038/s41375-018-0163-4
Gao W, Li J, Jian Y, Yang G, Wu Y, Li Y, et al. Immunoparesis in Symptomatic Multiple Myeloma at Diagnosis Affects PFS with Bortezomib-Containing Induction Therapy, but Not ASCT Consolidation. Int J Hematol. 2019 Feb;109(2):169-174. https://doi.org/10.1007/s12185-018-2547-7
Ribeiro T, Freitas J, Marques A, Tavares M, Pereira D, Chacim S, et al. Immunoparesis at diagnosis is an adverse prognostic factor for progression free-survival and overall survival in multiple myeloma. HemaSphere. 2020;4(Suppl.1):472.
Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V, et al. Ratio of Involved/Uninvolved Immunoglobulin Quantification by HevyliteTM Assay: Clinical and Prognostic Impact in Multiple Myeloma. Exp Hematol Oncol. 2012; 1(1): 9. https://doi.org/10.1186/2162-3619-1-9
González-Calle V, Cerdá S, Labrador J, Sobejano E, González-Mena B, Aguilera C, et al. Recovery of polyclonal immunnoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica. 2017;102(2):922-931. https://doi.org/10.3324/haematol.2016.158345
Rodríguez-Otero P, Paiva B, San-Miguel JF. Roadmap to cure multiple myeloma. Cancer Treat Rev. 2021; 100:102284. https://doi.org/10.1016/j.ctrv.2021.102284
Ríos-Tamayo R, Sánchez MJ, Puerta JM, Sainz J, Chang DY-L, Rodríguez T, et al. Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol.2015;39(5):693-9. https://doi.org/10.1016/j.canep.2015.08.002
Chang-Chan DYL, Ríos-Tamayo R, Rodríguez Barranco M, Redondo-Sánchez D, González Y, Marcos-Gragera R, et al. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol. 2021;23(7):1429-1439. https://doi.org/10.1007/s12094-020-02541-1
Garcia de Veas Silva JL, Gonzalez Cejudo MT, Garcia Perojil Jimenez A, Garcia Lopez Velez MDS, Garcia Rios Tamayo R, Garcia Bermudo Guitarte C. HLC pair suppression as a risk factor for bacterial bloodstream infections and early mortality in newly diagnosed intact immunoglobulin multiple myeloma patients. Front Oncol. 2021;11:599532. https://doi.org/10.3389/fonc.2021.599532
Bebnowska D, Hrynkiewicz R, Grywalska EE, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska I, et al. Immunological prognostic factors in multiple myeloma. Int J Mol Sci. 2021:22(7):3587. https://doi.org/10.3390/ijms22073587
Zhaoyun L, Rong F. Predictive role of immune profiling for survival of multiple myeloma patients. Front Immunnol. 2021;12:663748. https://doi.org/10.3389/fimmu.2021.663748
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Ríos-Tamayo R et al